Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.65 |
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8630173 | 0.92 | L3MBTL1 (0.67) | CASP2NAAAL3MBTL1FAAHGAA | |
| SCHEMBL23280900 | 0.92 | L3MBTL1 (0.67) | CASP2NAAAL3MBTL1FAAHGAA | |
| SCHEMBL27753495 | 0.88 | L3MBTL1 (0.62) | CASP2NAAAL3MBTL1FAAHGAA | |
| SCHEMBL2616415 | 0.87 | CASP2 (0.66) | CASP2NAAAL3MBTL1FAAHEPHX1 | |
| SCHEMBL2583169 | 0.86 | NAAA (0.59) | CASP2NAAAL3MBTL1FAAHGAA | |
| SCHEMBL13129293 | 0.86 | CASP2 (0.69) | CASP2NAAAL3MBTL1FAAHEPHX1 | |
| SCHEMBL4093621 | 0.86 | CASP2 (0.69) | CASP2NAAAL3MBTL1FAAHEPHX1 | |
| SCHEMBL22211254 | 0.85 | CASP2 (0.87) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL7887680 | 0.85 | CASP2 (0.87) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL13700142 | 0.85 | CASP2 (0.87) | CASP2NAAAFAAHEPHX1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770442-B2 | Self-assembling amphiphilic polymers as anti-cancer agents | ALLEXCEL INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | ALLEXCEL., INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | CD44, EPCAM, EGFR | CASP2 3257/4885NAAA 1109/4885L3MBTL1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.